Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin

Sabrina Bagaglio(Vita-Salute San Raffaele University), Giulia Morsica(Vita-Salute San Raffaele University), Filippo Trentini(Bocconi University), Emanuela Messina(Vita-Salute San Raffaele University), Andrea Andolina, Hamid Hasson(Vita-Salute San Raffaele University), Marco Merli(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Caterina Uberti‐Foppa(Vita-Salute San Raffaele University), Adriano Lazzarin(Vita-Salute San Raffaele University), Clelia Di Serio(Vita-Salute San Raffaele University), L. Porrino(San Raffaele University of Rome)
Medicine
October 1, 2015
10.1097/md.0000000000001876
Cited by 11

Related Papers

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
|The Lancet|2009|620
Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV
|The Lancet|1992|393
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391
Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access
|The Lancet|2022|286